# Ozempic vs Wegovy vs Mounjaro: The Complete GLP-1 Brand Comparison Guide (2026)
If you've searched "ozempic vs wegovy" or "mounjaro vs ozempic" recently, you're not alone. These three brand names collectively generate over 85,000 monthly searches — and for good reason. They represent the front line of GLP-1 receptor agonist therapy, the fastest-growing drug class in modern medicine.
This guide breaks down each brand by mechanism, clinical efficacy, dosing, and research context — so you understand not just what these drugs are, but how the underlying peptide compounds (semaglutide and tirzepatide) are studied at the API level.
> Research disclaimer: Ozempic, Wegovy, and Mounjaro are FDA-approved prescription medications indicated for specific clinical uses. This article is for educational and research purposes only. Research peptides are sold for laboratory research only and are not intended for human use.
---
What Are Ozempic, Wegovy, and Mounjaro?
All three are injectable therapies based on GLP-1 receptor agonist peptides — but they differ in compound, indication, and dosing range.
| Brand | Compound | Mechanism | Primary Indication |
|---|---|---|---|
| Ozempic | Semaglutide (0.5–2 mg weekly) | GLP-1 agonist | Type 2 diabetes |
| Wegovy | Semaglutide (2.4 mg weekly) | GLP-1 agonist | Chronic weight management |
| Mounjaro / Zepbound | Tirzepatide (2.5–15 mg weekly) | Dual GLP-1 + GIP agonist | Type 2 diabetes / weight management |
The key distinction: Ozempic and Wegovy use the same molecule (semaglutide) at different doses. Mounjaro (branded as Zepbound for weight loss) uses tirzepatide — a structurally distinct dual-agonist that simultaneously activates both GLP-1 and GIP receptors.
---
Semaglutide Deep Dive: Ozempic vs Wegovy
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist with 94% amino acid homology to endogenous GLP-1. Developed by Novo Nordisk, it was engineered with a C18 fatty acid chain that enables albumin binding — extending its half-life to approximately 7 days, which allows once-weekly dosing.
At the receptor level, semaglutide:
- •Stimulates glucose-dependent insulin secretion
- •Suppresses glucagon release
- •Slows gastric emptying
- •Activates hypothalamic satiety centers via GLP-1R signaling in the CNS
For researchers studying the semaglutide compound in detail, these receptor dynamics — particularly the CNS satiety signaling and gastric motility effects — are among the most active areas of current research.
Ozempic: The Diabetes Formulation
Ozempic (semaglutide 0.25–2 mg subcutaneous, once weekly) was FDA-approved in December 2017 for adults with type 2 diabetes to improve glycemic control and reduce cardiovascular risk.
Dosing escalation:
- •Weeks 1–4: 0.25 mg (initiation dose, not therapeutic)
- •Weeks 5–8: 0.5 mg
- •After week 8: 1 mg or 2 mg (maintenance)
SUSTAIN trial data (key findings):
The SUSTAIN program comprised 8 Phase 3 trials. Key glycemic results:
- •SUSTAIN-1: A1C reduction of 1.5% (0.5 mg) and 1.6% (1 mg) vs placebo
- •SUSTAIN-6 (cardiovascular outcomes): 26% reduction in MACE (major adverse cardiovascular events)
- •SELECT trial (2023): 20% reduction in cardiovascular events in non-diabetic patients with obesity
The SELECT trial was landmark — it demonstrated cardiovascular benefit in overweight/obese adults without diabetes, which opened the door to Wegovy's expanded cardiovascular indication.
Wegovy: The Weight Loss Formulation
Wegovy (semaglutide 2.4 mg subcutaneous, once weekly) was FDA-approved in June 2021 specifically for chronic weight management in adults with BMI ≥ 30, or ≥ 27 with at least one weight-related condition.
The 2.4 mg dose is meaningfully higher than the maximum 2 mg Ozempic dose — achieved through a longer titration schedule (16–20 weeks vs 8 weeks for Ozempic).
Titration schedule for Wegovy:
- •Weeks 1–4: 0.25 mg
- •Weeks 5–8: 0.5 mg
- •Weeks 9–12: 1.0 mg
- •Weeks 13–16: 1.7 mg
- •Week 17+: 2.4 mg (maintenance)
STEP trial data (weight loss efficacy):
| Trial | Population | Mean Weight Loss |
|---|---|---|
| STEP 1 | Obesity, no diabetes | 14.9% body weight |
| STEP 2 | Obesity + type 2 diabetes | 9.6% body weight |
| STEP 3 | Obesity + intensive behavioral therapy | 16.0% body weight |
| STEP 4 | Continued Wegovy vs switching to placebo | +6.9% regain on discontinuation |
STEP 4 is particularly notable for researchers: it demonstrated that weight regain on discontinuation is substantial and rapid — highlighting that GLP-1-driven weight management requires ongoing treatment.
Ozempic vs Wegovy: Are They the Same Drug?
Chemically: yes. Both contain semaglutide. The distinction is:
1. Dose: Wegovy's 2.4 mg is the highest approved semaglutide dose; Ozempic maxes at 2 mg
2. Indication: Ozempic = glycemic control in T2D; Wegovy = chronic weight management
3. Titration: Wegovy uses a longer ramp to minimize GI side effects at higher doses
4. Off-label use: Many providers have prescribed Ozempic off-label for weight loss (particularly during Wegovy supply shortages), which is why the search confusion is so common
For research purposes, both are based on the same semaglutide API — which is why semaglutide research supplier comparisons treat them as the same compound class.
---
Tirzepatide Deep Dive: Mounjaro and Zepbound
What Is Tirzepatide?
Tirzepatide is a "twincretin" — a single peptide molecule that is a co-agonist at both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Developed by Eli Lilly, it was designed using GIP as the structural backbone, with GLP-1 receptor agonist activity incorporated via specific amino acid substitutions.
This dual mechanism creates effects that appear synergistic rather than simply additive:
- •GLP-1R activation: Insulin secretion, glucagon suppression, satiety signaling, gastric motility reduction
- •GIPR activation: Enhanced insulin secretion, potential direct adipose tissue effects, reduced nausea relative to GLP-1 alone, possible central appetite modulation
The GIP component may also modulate the tolerability profile — tirzepatide at equivalent weight loss efficacy tends to show lower rates of nausea/vomiting than semaglutide in head-to-head analyses, though direct comparison trials are ongoing.
For a detailed mechanistic comparison at the compound level, see our semaglutide vs tirzepatide research comparison.
Mounjaro (Diabetes) and Zepbound (Weight Loss)
Unlike semaglutide's Ozempic/Wegovy split, tirzepatide's two brand names use the same dosing range:
- •Mounjaro: FDA-approved May 2022 for type 2 diabetes
- •Zepbound: FDA-approved November 2023 for chronic weight management
- •Both use tirzepatide 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (weekly, subcutaneous)
SURPASS trial data (diabetes):
| Trial | Comparator | A1C Reduction (15 mg) | Weight Loss (15 mg) |
|---|---|---|---|
| SURPASS-1 | Placebo | -2.1% | -9.5 kg |
| SURPASS-2 | Semaglutide 1 mg | -2.3% vs -1.9% | -12.4 kg vs -6.2 kg |
| SURPASS-3 | Insulin degludec | -2.4% vs -1.9% | -13.9 kg vs +3.0 kg |
SURPASS-2 is the most cited head-to-head: tirzepatide 15 mg outperformed semaglutide 1 mg (note: not 2 mg) on both A1C reduction and weight loss.
SURMOUNT trial data (weight management):
| Trial | Population | Weight Loss (15 mg) |
|---|---|---|
| SURMOUNT-1 | Obesity, no diabetes | 20.9% body weight |
| SURMOUNT-2 | Obesity + type 2 diabetes | 15.7% body weight |
| SURMOUNT-3 | Led-in intensive lifestyle + tirzepatide | 26.6% body weight |
| SURMOUNT-4 | Continued vs discontinued at 36 weeks | +14.8% regain on discontinuation |
SURMOUNT-1's 20.9% mean weight loss at the highest dose approached outcomes previously seen only with bariatric surgery, making tirzepatide the highest-efficacy approved pharmacotherapy for obesity to date.
---
Head-to-Head: Ozempic vs Wegovy vs Mounjaro
Efficacy Comparison
| Metric | Ozempic (2 mg) | Wegovy (2.4 mg) | Mounjaro (15 mg) |
|---|---|---|---|
| A1C reduction | ~1.6–1.8% | ~1.6% | ~2.1–2.4% |
| Weight loss (mean) | ~6–8% | ~14.9–16% | ~20.9% |
| Cardiovascular benefit | Yes (SELECT trial) | Yes (per SELECT data) | Pending (SURPASS-CVOT) |
| Weekly dosing | Yes | Yes | Yes |
| GI tolerability | Moderate | Moderate | Slightly better |
Critical caveat: These trials used different populations, doses, and comparators. Direct randomized head-to-head trials of Wegovy 2.4 mg vs Mounjaro 15 mg are ongoing but not yet published. The efficacy numbers reflect each drug's own trial programs.
Dosing and Administration
All three are subcutaneous injections, administered once weekly using pen-injector devices.
| Ozempic | Wegovy | Mounjaro / Zepbound | |
|---|---|---|---|
| Manufacturer | Novo Nordisk | Novo Nordisk | Eli Lilly |
| Max dose | 2 mg | 2.4 mg | 15 mg |
| Titration weeks | ~8 | ~16–20 | ~20–24 |
| Prefilled pen | Yes | Yes | Yes |
| Storage | Refrigerated (room temp up to 56 days) | Refrigerated | Refrigerated (room temp up to 21 days) |
Side Effect Profile
All three share a class effect profile driven by GLP-1 receptor activation:
- •Most common: Nausea, vomiting, diarrhea, constipation (especially during titration)
- •Less common: Injection site reactions, fatigue, abdominal pain
- •Rare/serious: Pancreatitis risk, gallbladder disease, thyroid C-cell tumor risk (rodent data only, human significance unclear)
Tirzepatide's GIP co-agonism may blunt some nausea signal — a hypothesis supported by SURMOUNT-1 tolerability data, though head-to-head GI comparison data is limited.
---
Research Context: Semaglutide and Tirzepatide as Research Peptides
Beyond their approved clinical applications, semaglutide and tirzepatide are actively studied at the API (active pharmaceutical ingredient) level by researchers. Research peptide suppliers provide these compounds for laboratory investigations into:
- •GLP-1R and GIPR receptor pharmacology
- •Metabolic syndrome animal models
- •Neuroinflammation and neuroprotection (CNS GLP-1R expression)
- •Cardiac and hepatic metabolic effects
- •Longevity and aging biology (emerging)
For researchers sourcing these compounds, the brand names are irrelevant — what matters is compound identity (semaglutide vs tirzepatide), purity specifications, and supplier COA data.
Our GLP-1 research peptide sources guide covers top-rated suppliers by purity, pricing, and COA transparency. For side-by-side API pricing and availability, see our compound comparison tool.
The tirzepatide research profile and semaglutide research profile provide full technical data including molecular weight, structure, stability parameters, and reconstitution protocols relevant to laboratory use.
---
Price Context: Brand vs Research API
The cost difference between FDA-approved branded drugs and research-grade APIs is dramatic:
| Format | Ozempic | Wegovy | Mounjaro | Research API (approx.) |
|---|---|---|---|---|
| List price/month | ~$900–$1,000 | ~$1,300–$1,400 | ~$1,000–$1,100 | $30–$80 (10 mg vial) |
| With insurance | $25–$150 copay | $25–$150 copay | $25–$150 copay | N/A |
| Without insurance | Full list price | Full list price | Full list price | Research wholesale |
The order-of-magnitude price difference reflects the regulatory approval process, manufacturing standards, and clinical-use liability — not a meaningful difference in peptide chemistry. Research APIs are not approved for human use and are purchased exclusively for laboratory investigation.
---
Which Brand Is Right? Clinical vs Research Perspectives
Clinical Perspective (consult your physician)
- •Ozempic: Best suited for patients with type 2 diabetes seeking glycemic control with cardiovascular risk reduction
- •Wegovy: Best suited for patients with obesity as the primary indication, or those prioritizing weight loss
- •Mounjaro/Zepbound: Best suited for patients who need maximum efficacy on both glycemic control and weight reduction, especially in type 2 diabetes
Insurance coverage, prior authorization requirements, and formulary status significantly affect access in practice.
Research Perspective
Researchers choose between semaglutide and tirzepatide APIs based on:
- •Mechanistic focus: GLP-1R-only (semaglutide) vs dual GLP-1R/GIPR (tirzepatide)
- •Protocol requirements: Established GLP-1 literature uses semaglutide; newer dual-agonist research uses tirzepatide
- •Availability and cost: Both are widely available from reputable research suppliers
For detailed supplier comparisons and pricing, our semaglutide vs tirzepatide research comparison covers the full API landscape.
---
Key Takeaways
1. Ozempic and Wegovy are the same compound (semaglutide) at different doses for different indications — weight loss efficacy is higher at Wegovy's 2.4 mg dose
2. Mounjaro/Zepbound is a distinct molecule (tirzepatide) with a dual GLP-1/GIP mechanism that produces greater weight loss in trials
3. STEP trials established Wegovy's 14.9% weight loss benchmark; SURMOUNT trials established Mounjaro's 20.9% — but these are not directly comparable
4. The SELECT trial expanded Ozempic/Wegovy's cardiovascular indication; Mounjaro's cardiovascular data (SURPASS-CVOT) is maturing
5. Research peptide APIs (semaglutide, tirzepatide) are studied separately from their branded formulations — for laboratory applications, supplier quality and purity documentation matter more than brand affiliation
---
References
1. Marso SP, et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." NEJM 2016; 375:1834-1844 (SUSTAIN-6)
2. Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." NEJM 2021; 384:989-1002 (STEP 1)
3. Lincoff AM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." NEJM 2023; 389:2221-2232 (SELECT)
4. Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." NEJM 2022; 387:205-216 (SURMOUNT-1)
5. Frías JP, et al. "Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes." NEJM 2021; 385:503-515 (SURPASS-2)
6. Davies M, et al. "Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)." Lancet 2021; 397:971-984
---
For research purposes only. Not intended for human use or as medical advice. Ozempic, Wegovy, Mounjaro, and Zepbound are FDA-approved prescription medications; consult a licensed healthcare provider for clinical guidance. Research-grade semaglutide and tirzepatide APIs are sold for laboratory research only.
---
Ongoing Research and 2026 Developments
Cardiovascular Research Expansion
The SELECT trial's 2023 results — showing 20% MACE reduction with semaglutide in non-diabetic obese patients — triggered a wave of mechanistic research into GLP-1's direct cardiovascular effects independent of weight loss. Proposed mechanisms under active investigation include:
- •Anti-inflammatory effects via GLP-1R expressed on macrophages and endothelial cells
- •Reduction in atherosclerotic plaque burden
- •Improved myocardial efficiency and cardiac output
- •Direct renal protective effects (nephroprotection studies ongoing)
Tirzepatide's SURMOUNT-MMO (cardiovascular outcomes) trial results are expected in 2024–2025, and will determine whether the dual GLP-1/GIP mechanism confers similar or superior cardiovascular protection.
Neurological and Addiction Research
An increasingly active area of GLP-1 research examines CNS GLP-1R expression. Semaglutide's ability to cross the blood-brain barrier (limited, but measurable) has prompted research into:
- •Neuroinflammation and Parkinson's disease (semaglutide vs liraglutide trials ongoing)
- •Alzheimer's disease risk reduction (EVOKE trial)
- •Addiction modulation — early human and animal data suggest GLP-1R activation reduces reward-seeking behavior for alcohol, opioids, and nicotine
- •ADHD and impulse control (preliminary observational data)
These applications are far from the approved indications but represent significant research interest in the semaglutide and tirzepatide compound classes.
Oral Formulations
Rybelsus (oral semaglutide 3–14 mg daily) is already approved for type 2 diabetes. Novo Nordisk has advanced oral semaglutide 25 mg and 50 mg formulations through Phase 3 for obesity — the OASIS-1 trial showed 17.4% weight loss at 50 mg, approaching injectable Wegovy efficacy. If approved, this would meaningfully change the accessibility landscape for semaglutide-based therapy.
Combination Approaches
Cagrilintide + semaglutide (CagriSema) — combining an amylin analog with GLP-1 — showed 22.7% weight loss in Phase 2, surpassing tirzepatide monotherapy efficacy in early data. This combination approach, and others pairing GLP-1 agonists with GIP, glucagon, amylin, or FGF21 analogs, represents the next wave of metabolic peptide research.
---
Frequently Asked Questions
Can I switch between Ozempic and Wegovy?
They are the same compound — your prescriber can adjust your dose between the two formulations depending on your indication and insurance coverage. However, switching should be managed medically, not self-directed.
Is Mounjaro stronger than Wegovy?
In terms of trial-reported weight loss outcomes, yes — SURMOUNT-1 (tirzepatide) showed ~20.9% weight loss vs STEP-1 (semaglutide/Wegovy) at ~14.9%. However, these trials used different populations and aren't directly comparable. Individual responses vary significantly.
Why did Ozempic become so famous?
Off-label prescribing of Ozempic for weight loss (at doses approved for diabetes) gained significant media attention in 2022–2023, particularly among high-profile individuals. This drove massive demand, contributing to the global semaglutide shortage that affected diabetic patients who depended on the drug for glycemic control.
What happened to compounded semaglutide?
During the shortage periods, the FDA's 503B pharmacy exemption allowed compounding pharmacies to produce semaglutide. Once Ozempic and Wegovy were removed from the FDA shortage list (early 2024), compounded versions lost their exemption status. This is a separate regulatory framework from research-grade API sourcing.
Are research peptides the same as Ozempic?
No. Research-grade semaglutide and tirzepatide APIs are sold exclusively for laboratory research under RUO (Research Use Only) labeling. They are not pharmaceutical-grade, not intended for human use, and are not equivalent to FDA-approved medications in regulatory status, manufacturing standards, or clinical application.